These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 36436175)

  • 41. Both Ox1R and Ox2R orexin receptors contribute to the cardiorespiratory response evoked from the perifornical hypothalamus.
    Beig MI; Horiuchi J; Dampney RA; Carrive P
    Clin Exp Pharmacol Physiol; 2015 Oct; 42(10):1059-67. PubMed ID: 26174505
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Causes and Consequences of Chronic Sleep Deficiency and the Role of Orexin.
    Mullington JM; Cunningham TJ; Haack M; Yang H
    Front Neurol Neurosci; 2021; 45():128-138. PubMed ID: 34052807
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Orexin receptors: pharmacology and therapeutic opportunities.
    Scammell TE; Winrow CJ
    Annu Rev Pharmacol Toxicol; 2011; 51():243-66. PubMed ID: 21034217
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Assessment of the abuse liability of a dual orexin receptor antagonist: a crossover study of almorexant and zolpidem in recreational drug users.
    Cruz HG; Hoever P; Chakraborty B; Schoedel K; Sellers EM; Dingemanse J
    CNS Drugs; 2014 Apr; 28(4):361-72. PubMed ID: 24627301
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Can the Orexin Antagonist Suvorexant Preserve the Ability to Awaken to Auditory Stimuli While Improving Sleep?
    Drake CL; Kalmbach DA; Cheng P; Roth T; Tran KM; Cuamatzi-Castelan A; Atkinson R; Singh M; Tonnu CV; Fellman-Couture C
    J Clin Sleep Med; 2019 Sep; 15(9):1285-1291. PubMed ID: 31538599
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia.
    Roecker AJ; Reger TS; Mattern MC; Mercer SP; Bergman JM; Schreier JD; Cube RV; Cox CD; Li D; Lemaire W; Bruno JG; Harrell CM; Garson SL; Gotter AL; Fox SV; Stevens J; Tannenbaum PL; Prueksaritanont T; Cabalu TD; Cui D; Stellabott J; Hartman GD; Young SD; Winrow CJ; Renger JJ; Coleman PJ
    Bioorg Med Chem Lett; 2014 Oct; 24(20):4884-90. PubMed ID: 25248679
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Discovery of dual orexin receptor antagonists (DORAs) for the treatment of insomnia.
    Coleman PJ; Cox CD; Roecker AJ
    Curr Top Med Chem; 2011; 11(6):696-725. PubMed ID: 21261591
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The efficacy and safety of dual orexin receptor antagonists in primary insomnia: A systematic review and network meta-analysis.
    Xue T; Wu X; Chen S; Yang Y; Yan Z; Song Z; Zhang W; Zhang J; Chen Z; Wang Z
    Sleep Med Rev; 2022 Feb; 61():101573. PubMed ID: 34902823
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Discovery of piperidine ethers as selective orexin receptor antagonists (SORAs) inspired by filorexant.
    Raheem IT; Breslin MJ; Bruno J; Cabalu TD; Cooke A; Cox CD; Cui D; Garson S; Gotter AL; Fox SV; Harrell CM; Kuduk SD; Lemaire W; Prueksaritanont T; Renger JJ; Stump C; Tannenbaum PL; Williams PD; Winrow CJ; Coleman PJ
    Bioorg Med Chem Lett; 2015 Feb; 25(3):444-50. PubMed ID: 25577040
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Discovery of dual orexin receptor antagonists with rat sleep efficacy enabled by expansion of the acetonitrile-assisted/diphosgene-mediated 2,4-dichloropyrimidine synthesis.
    Roecker AJ; Mercer SP; Harrell CM; Garson SL; Fox SV; Gotter AL; Prueksaritanont T; Cabalu TD; Cui D; Lemaire W; Winrow CJ; Renger JJ; Coleman PJ
    Bioorg Med Chem Lett; 2014 May; 24(9):2079-85. PubMed ID: 24704030
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and safety of almorexant in adult chronic insomnia: a randomized placebo-controlled trial with an active reference.
    Black J; Pillar G; Hedner J; Polo O; Berkani O; Mangialaio S; Hmissi A; Zammit G; Hajak G
    Sleep Med; 2017 Aug; 36():86-94. PubMed ID: 28735928
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Role of orexin receptors in the ventral tegmental area on acquisition and expression of morphine-induced conditioned place preference in the rats.
    Farahimanesh S; Zarrabian S; Haghparast A
    Neuropeptides; 2017 Dec; 66():45-51. PubMed ID: 28890208
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In Vitro and In Silico Characterization of Lemborexant (E2006), a Novel Dual Orexin Receptor Antagonist.
    Beuckmann CT; Suzuki M; Ueno T; Nagaoka K; Arai T; Higashiyama H
    J Pharmacol Exp Ther; 2017 Aug; 362(2):287-295. PubMed ID: 28559480
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Preclinical and clinical efficacy of orexin receptor antagonist Lemborexant (Dayvigo
    Koebisu M; Koyama N; Nishida M; Muramoto K
    Nihon Yakurigaku Zasshi; 2021; 156(2):114-119. PubMed ID: 33642529
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Orexin/hypocretin and major psychiatric disorders.
    Lin CC; Huang TL
    Adv Clin Chem; 2022; 109():185-212. PubMed ID: 35953127
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Orexin-1 and orexin-2 receptor antagonists reduce ethanol self-administration in high-drinking rodent models.
    Anderson RI; Becker HC; Adams BL; Jesudason CD; Rorick-Kehn LM
    Front Neurosci; 2014; 8():33. PubMed ID: 24616657
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications.
    Herring WJ; Roth T; Krystal AD; Michelson D
    J Sleep Res; 2019 Apr; 28(2):e12782. PubMed ID: 30338596
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Investigation of orexin-2 selective receptor antagonists: Structural modifications resulting in dual orexin receptor antagonists.
    Skudlarek JW; DiMarco CN; Babaoglu K; Roecker AJ; Bruno JG; Pausch MA; O'Brien JA; Cabalu TD; Stevens J; Brunner J; Tannenbaum PL; Wuelfing WP; Garson SL; Fox SV; Savitz AT; Harrell CM; Gotter AL; Winrow CJ; Renger JJ; Kuduk SD; Coleman PJ
    Bioorg Med Chem Lett; 2017 Mar; 27(6):1364-1370. PubMed ID: 28216403
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Role of orexin-A in the ventrolateral preoptic area on components of total energy expenditure.
    Coborn JE; DePorter DP; Mavanji V; Sinton CM; Kotz CM; Billington CJ; Teske JA
    Int J Obes (Lond); 2017 Aug; 41(8):1256-1262. PubMed ID: 28392556
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identification of a novel series of orexin receptor antagonists with a distinct effect on sleep architecture for the treatment of insomnia.
    Betschart C; Hintermann S; Behnke D; Cotesta S; Fendt M; Gee CE; Jacobson LH; Laue G; Ofner S; Chaudhari V; Badiger S; Pandit C; Wagner J; Hoyer D
    J Med Chem; 2013 Oct; 56(19):7590-607. PubMed ID: 23964859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.